Venetoclax + Azacitidine + Cytarabine + Methotrexate + Hydrocortisone + Leucovorin + Dexamethasone + Vincristine + Doxorubicin + Dexrazoxane + Calaspargase Pegol + Erwinia asparaginase

Phase 1Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndromes, de Novo

Conditions

Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage

Trial Timeline

Mar 29, 2023 → Jul 2, 2030

NCT ID

NCT05292664

About Venetoclax + Azacitidine + Cytarabine + Methotrexate + Hydrocortisone + Leucovorin + Dexamethasone + Vincristine + Doxorubicin + Dexrazoxane + Calaspargase Pegol + Erwinia asparaginase

Venetoclax + Azacitidine + Cytarabine + Methotrexate + Hydrocortisone + Leucovorin + Dexamethasone + Vincristine + Doxorubicin + Dexrazoxane + Calaspargase Pegol + Erwinia asparaginase is a phase 1 stage product being developed by AbbVie for Myelodysplastic Syndromes, de Novo. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05292664. Target conditions include Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated.

What happened to similar drugs?

7 of 19 similar drugs in Myelodysplastic Syndromes, de Novo were approved

Approved (7) Terminated (7) Active (7)

✅decitabine + azacitidineEisaiApproved

✅DeferasiroxNovartisApproved

✅ICL670/DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

✅DeferasiroxNovartisApproved

✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05292664	Phase 1	Recruiting	Mar 29, 2023	Jul 2, 2030	Myelodysplastic Syndromes, de Novo

Competing Products

20 competing products in Myelodysplastic Syndromes, de Novo

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	23
JSP191	Jasper Therapeutics	Phase 1	11
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	35
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	35
Decitabine + Valproic Acid	Eisai	Phase 2	35
decitabine + decitabine	Eisai	Phase 2	35
decitabine + azacitidine	Eisai	Approved	35
Decitabine	Eisai	Phase 2	27
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	29
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	35
Subcutaneous Decitabine	Eisai	Phase 1	21
Decitabine	Eisai	Phase 2	35
Galunisertib + Placebo	Eli Lilly	Phase 2/3	38
DSP-7888	Sumitomo Pharma	Phase 1/2	32
TP-0184	Sumitomo Pharma	Phase 1/2	24
Decitabine	Johnson & Johnson	Phase 2	35
Epoetin alfa	Johnson & Johnson	Phase 2	27
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	35